Skip to content
Markets News
Stocks1 min read

Disc Medicine plans FDA filing after positive bitopertin Phase 3 data

Makkler Newsroom
October 20, 2026 · Based on reporting by finanzen.net

The company reported lower PPIX levels and more pain-free light exposure, and plans a new FDA submission by year-end.

Key takeaways

  • Bitopertin met the primary and secondary goals in the APOLLO Phase 3 study.
  • Disc Medicine plans to resubmit its FDA application by the end of 2026.

Disc Medicine plans to resubmit bitopertin for FDA approval by the end of 2026 after the drug met all primary and secondary goals in the Phase 3 APOLLO study. The company also announced a $350 million public stock placement to fund preparations for a potential launch and other pipeline projects.

Bitopertin reduced blood levels of PPIX by 41.4% compared with placebo. In the study’s sixth month, patients gained 12.2 hours of pain-free light exposure per month versus the control group.

Disc Medicine is targeting an FDA decision by mid-2027. As of Monday’s close, its shares traded at $78.93, up 38.86% from the previous close.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.